114 results
8-K
EX-99.1
NVRO
Nevro Corp
1 Nov 23
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
4:07pm
of 2022, excluding $105.0 million of certain litigation credits in the third quarter of 2022. The increase in operating expenses was primarily due … to litigation and personnel related costs, partially offset by a decrease in stock-based compensation. Litigation-related legal expenses were $4.3
8-K
EX-99.1
NVRO
Nevro Corp
2 Nov 22
Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
4:14pm
2022 Income from Operations of $82.1 Million, or Non-GAAP Loss from Operations of $22.9 Million Excluding Credits Related to Patent Litigation … of litigation-related credits. Including these credits, GAAP operating expenses were a net gain of $12.8 million. Operating expenses were $91.1 million
8-K
EX-99.1
NVRO
Nevro Corp
8 Nov 21
Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance
4:18pm
Third Quarter 2021 Net Loss from Operations of $46.4 Million, or $26.4 Million excluding $20 Million Patent Litigation Judgement; Third Quarter 2021 … in the third quarter of 2019. The year-over-year increase in operating expenses was primarily related to all patent litigation related expenses, PDN
8-K
EX-99.1
NVRO
Nevro Corp
23 Feb 22
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
12:00am
associated with patent litigation were $6.1 million for the fourth quarter of 2021, compared to $5.1 million in the prior year period and $1.7 million … in 2019. Net of all patent litigation and PDN investment expenses, total other operating expenses were $7.5 million lower than 2019.
Net loss from
8-K
EX-99.1
NVRO
Nevro Corp
21 Feb 24
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
4:09pm
legal costs. The fourth quarter additionally included $3.0 million in one-time expense related to the Vyrsa acquisition. Litigation-related legal … on extinguishment of debt, restructuring charges, litigation-related credits and expenses, gain on extinguishment of debt, and non-cash items such as changes
8-K
EX-99.1
a7ie uf10og
19 Apr 23
Results of Operations and Financial Condition
5:07pm
8-K
EX-99.1
n0iblz6
25 Feb 20
Nevro Reports Fourth Quarter and Full Year 2019 Financial Results
4:22pm
8-K
EX-99.1
4ra84o285yfm318t8e
5 May 20
Nevro Reports First Quarter 2020 Financial Results
4:16pm
8-K
EX-99.1
b8946ddi1k
5 May 21
Nevro Reports First Quarter 2021 Financial Results and Updates 2021 Guidance
4:16pm
8-K
EX-99.1
i7ilqvv40 0f
4 May 22
Nevro Reports First Quarter 2022 Financial Results, Provides Second Quarter 2022 Guidance and Reiterates Full-Year 2022 Guidance
4:18pm
8-K
EX-99.1
ohcty00 7pkjb7jriz5m
24 Feb 21
Nevro Reports Fourth Quarter and Full Year 2020 Financial Results
4:26pm
8-K
EX-99.1
5t6d 76u4t
26 Apr 23
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
4:13pm
8-K
EX-99.1
et2py1 6e
1 Aug 23
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
4:10pm
8-K
EX-99.1
icowmfain hn13k
3 Aug 22
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
4:18pm
8-K
EX-99.1
ek3vvc6ihv1zdn9nibg
4 Aug 21
Nevro Reports Second Quarter 2021 Financial Results and Provides Third Quarter of 2021 Guidance
4:20pm
8-K
EX-99.1
jmbssqt6
6 Nov 19
Nevro Reports Third Quarter 2019 Financial Results
4:16pm
8-K
EX-99.1
gac 8exy892ht
7 May 24
Nevro Reports First-Quarter 2024 Financial Results
4:11pm
8-K
EX-99.1
c1mzw3wboll
5 Aug 20
Nevro Announces Second Quarter 2020 Financial Results
4:19pm
8-K
EX-99.1
p2awn4qt19ker7vkxtsi
5 Nov 20
Nevro Announces Third Quarter 2020 Financial Results
4:18pm